HUTCHMED (China) Limited
http://www.hmplglobal.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From HUTCHMED (China) Limited
Multiple Chinese Firms Expand Global Phase III Trials To Japan
The efforts add up to a new trend after Chinese pharma firms embarked on a quest to launch pivotal Phase II or III trials worldwide, especially in the US and Europe, over the past decade. Meanwhile, BeiGene, Hengrui and others are advancing late-stage programs in the US.
Innovative Drugs: China Gains Deals, But Financing Amounts Drop
China has seen a “milestone year for the overseas launch of domestically produced innovative drugs.”
HUTCHMED Switches Clinical Strategy To Rely On Partnerships For Late-Stage Assets In US
Having initiated China-only Phase III trials with three oncology and autoimmune drug candidates, HUTCHMED is looking for partnerships to take the molecules to the clinic in the US.
New Oncologics Overwhelmingly Approved In US Before EU
Ninety-five percent of novel cancer treatments approved in both the US and Europe received the FDA’s OK first, but Europe usually followed within a year, a Pink Sheet analysis shows.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Chi-Med
- Hutchison Whampoa
- Sinopharm Pharmaceuticals Company Limited
- Hutchison MediPharma Limited
- Hutchison China MediTech Limited
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice